|
Nov 26
|
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now
|
|
Nov 12
|
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
|
|
Oct 3
|
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts?
|
|
Aug 28
|
Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
|
|
Aug 26
|
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
|
|
Jul 30
|
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
|
|
Jun 1
|
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
|
|
May 30
|
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
|
|
May 23
|
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
|
|
May 9
|
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
|
|
May 7
|
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 1
|
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
|
|
Apr 24
|
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
|
|
Apr 19
|
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
|
|
Apr 12
|
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
|
|
Apr 2
|
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
|
|
Mar 12
|
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
|
|
Mar 6
|
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
|
|
Feb 28
|
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
|
|
Jan 9
|
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
|